ES3042059T3 - Methods to determine kdm1a target engagement and chemoprobes useful therefor - Google Patents

Methods to determine kdm1a target engagement and chemoprobes useful therefor

Info

Publication number
ES3042059T3
ES3042059T3 ES17716799T ES17716799T ES3042059T3 ES 3042059 T3 ES3042059 T3 ES 3042059T3 ES 17716799 T ES17716799 T ES 17716799T ES 17716799 T ES17716799 T ES 17716799T ES 3042059 T3 ES3042059 T3 ES 3042059T3
Authority
ES
Spain
Prior art keywords
kdm1a
trans
compound
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17716799T
Other languages
English (en)
Spanish (es)
Inventor
Gonzalez Elena Carceller
Tamara Maes
Crusat Cristina Mascaro
Munoz Alberto Ortega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oryzon Genomics SA
Original Assignee
Oryzon Genomics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics SA filed Critical Oryzon Genomics SA
Application granted granted Critical
Publication of ES3042059T3 publication Critical patent/ES3042059T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES17716799T 2016-03-16 2017-03-16 Methods to determine kdm1a target engagement and chemoprobes useful therefor Active ES3042059T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382119 2016-03-16
PCT/EP2017/056330 WO2017158136A1 (en) 2016-03-16 2017-03-16 Methods to determine kdm1a target engagement and chemoprobes useful therefor

Publications (1)

Publication Number Publication Date
ES3042059T3 true ES3042059T3 (en) 2025-11-18

Family

ID=55794924

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17716799T Active ES3042059T3 (en) 2016-03-16 2017-03-16 Methods to determine kdm1a target engagement and chemoprobes useful therefor

Country Status (5)

Country Link
US (2) US11034991B2 (https=)
EP (1) EP3430015B9 (https=)
JP (1) JP2019512546A (https=)
ES (1) ES3042059T3 (https=)
WO (1) WO2017158136A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
CA3017408C (en) 2016-03-15 2025-08-19 Oryzon Genomics, S.A. LSD1 INHIBITOR COMBINATIONS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIS
WO2017158136A1 (en) * 2016-03-16 2017-09-21 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor
RS58951B1 (sr) 2016-06-10 2019-08-30 Oryzon Genomics Sa Lečenje multiple skleroze
WO2020152280A1 (en) * 2019-01-24 2020-07-30 Fundación Pública Andaluza Progreso Y Salud Lsd1 inhibitors for use in the treatment of type 2 diabetes
WO2021197371A1 (zh) * 2020-03-31 2021-10-07 南京金斯瑞生物科技有限公司 一种含有刚性连接子的生物偶联物

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2341134B1 (en) 2003-01-31 2014-08-27 Promega Corporation Covalent tethering of functional groups to proteins
WO2007021839A2 (en) 2005-08-10 2007-02-22 Johns Hopkins University Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
CA2668286C (en) * 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
EP2142287A4 (en) 2007-04-13 2012-05-23 Univ Johns Hopkins INHIBITORS OF LYSINPECIFIC DEMETHYLASE
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
JPWO2010143582A1 (ja) 2009-06-11 2012-11-22 公立大学法人名古屋市立大学 フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤
EP2467359A4 (en) 2009-08-18 2013-01-09 Univ Johns Hopkins (BIS-) UREA- AND (BIS-) THIOMINE COMPOUNDS AS EPIGENE MODULATORS OF THE LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF DISEASE TREATMENT THEREWITH
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
CA2796726C (en) 2010-04-19 2021-02-16 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
BR112012027062B8 (pt) 2010-04-20 2021-05-25 Fond Ieo composto, processo para a preparação de um composto e usos do mesmo
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
BR112013002164B1 (pt) 2010-07-29 2021-11-09 Oryzon Genomics S.A. Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica
WO2012034116A2 (en) 2010-09-10 2012-03-15 The Johns Hopkins University Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012071469A2 (en) 2010-11-23 2012-05-31 Nevada Cancer Institute Histone demethylase inhibitors and uses thereof for treatment o f cancer
PH12013501871A1 (en) 2011-03-25 2019-06-03 Glaxosmithkline Ip No 2 Ltd Cyclopropylamines as lsd1 inhibitors
PE20141202A1 (es) 2011-08-09 2014-10-03 Takeda Pharmaceutical Compuesto de ciclopropanoamina
SI2744330T1 (sl) 2011-08-15 2020-11-30 University Of Utah Research Foundation Substituirani (E)-N'-(1-feniletiliden) benzohidrazidni analogi kot inhibitorji histon-demetilaze
US9289415B2 (en) 2011-09-01 2016-03-22 The Brigham And Women's Hospital, Inc. Treatment of cancer
JP6046154B2 (ja) * 2011-10-20 2016-12-14 オリソン ヘノミクス エセ． アー． Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
CA2887598A1 (en) * 2012-10-12 2014-04-17 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
WO2014084298A1 (ja) 2012-11-28 2014-06-05 京都府公立大学法人 リシン構造を有するｌｓｄ1選択的阻害薬
WO2014085613A1 (en) 2012-11-30 2014-06-05 Mccord Darlene E Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition
EP2740474A1 (en) 2012-12-05 2014-06-11 Instituto Europeo di Oncologia S.r.l. Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
CN103054869A (zh) 2013-01-18 2013-04-24 郑州大学 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用
WO2014164867A1 (en) 2013-03-11 2014-10-09 Imago Biosciences Kdm1a inhibitors for the treatment of disease
EP2969435B1 (en) 2013-03-15 2021-11-03 Promega Corporation Substrates for covalent tethering of proteins to functional groups or solid surfaces
BR112015032113B1 (pt) 2013-06-19 2019-01-29 University Of Utah Research Foundation análogos de (e)-n’-(1-feniletilideno)benzohidrazida substituídos como inibidores de histona demetilase
CN103319466B (zh) 2013-07-04 2016-03-16 郑州大学 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用
ES2734209T3 (es) 2013-08-06 2019-12-04 Imago Biosciences Inc Inhibidores de KDM1A para el tratamiento de enfermedades
US9186391B2 (en) 2013-08-29 2015-11-17 Musc Foundation For Research Development Cyclic peptide inhibitors of lysine-specific demethylase 1
WO2015031564A2 (en) 2013-08-30 2015-03-05 University Of Utah Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors
CA3161836A1 (en) 2013-12-11 2015-06-18 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
WO2015120281A1 (en) 2014-02-07 2015-08-13 Musc Foundation For Research Development Aminotriazole- and aminotetrazole-based kdm1a inhibitors as epigenetic modulators
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3105218B1 (en) 2014-02-13 2019-09-25 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
JP6602779B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
CA2941716A1 (en) 2014-03-07 2015-09-11 The Johns Hopkins University Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
CN103893163B (zh) 2014-03-28 2016-02-03 中国药科大学 2-([1，1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用
MY180575A (en) 2014-04-11 2020-12-02 Takeda Pharmaceuticals Co Cyclopropanamine compound and use thereof
CN103961340B (zh) 2014-04-30 2019-06-25 南通中国科学院海洋研究所海洋科学与技术研究发展中心 一类lsd1抑制剂及其应用
KR102400920B1 (ko) 2014-05-01 2022-05-20 셀젠 콴티셀 리서치, 인크. 리신 특이적 데메틸라제-1의 억제제
WO2015181380A1 (en) 2014-05-30 2015-12-03 Ieo - Istituto Europeo Di Oncologia S.R.L. Cyclopropylamine compounds as histone demethylase inhibitors
DK3160956T3 (da) 2014-06-27 2020-08-31 Celgene Quanticel Res Inc Inhibitorer af lysin-specifik demethylase-1
CN104119280B (zh) 2014-06-27 2016-03-16 郑州大学 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用
JP6525422B2 (ja) 2014-07-03 2019-06-05 セルジーン クオンティセル リサーチ，インク． リジン特異的なデメチラーゼ−１の阻害剤
FI3511319T3 (fi) 2014-07-03 2023-07-20 Celgene Quanticel Res Inc Lysiinispesifisen demetylaasi-1:n inhibiittoreita
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
AU2015311805B2 (en) 2014-09-05 2020-04-02 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
EP2993175A1 (en) 2014-09-05 2016-03-09 IEO - Istituto Europeo di Oncologia Srl Thienopyrroles as histone demethylase inhibitors
WO2016123387A1 (en) 2015-01-30 2016-08-04 Genentech, Inc. Therapeutic compounds and uses thereof
CA2976350C (en) 2015-02-12 2023-09-19 Hugh Young Rienhoff, Jr. Kdm1a inhibitors for the treatment of disease
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
CN106045862B (zh) 2015-04-10 2019-04-23 上海迪诺医药科技有限公司 环丙胺类螺(杂)环化合物、其药物组合物及应用
US10526287B2 (en) 2015-04-23 2020-01-07 Constellation Pharmaceuticals, Inc. LSD1 inhibitors and uses thereof
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
WO2017004519A1 (en) 2015-07-02 2017-01-05 University Of Utah Research Foundation Substituted benzohydrazide analogs as histone demethylase inhibitors
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
WO2017158136A1 (en) * 2016-03-16 2017-09-21 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor

Also Published As

Publication number Publication date
US11034991B2 (en) 2021-06-15
EP3430015B9 (en) 2025-12-31
US12195783B2 (en) 2025-01-14
WO2017158136A1 (en) 2017-09-21
EP3430015B1 (en) 2025-08-06
EP3430015A1 (en) 2019-01-23
US20220389478A1 (en) 2022-12-08
JP2019512546A (ja) 2019-05-16
EP3430015C0 (en) 2025-08-06
US20190085372A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
ES3042059T3 (en) Methods to determine kdm1a target engagement and chemoprobes useful therefor
US20250388562A1 (en) Small molecule degraders of helios and methods of use
TWI690318B (zh) 作爲ｂａｃｅ１抑制劑之２-胺基-６-（二氟甲基）-５,５-二氟-６-苯基-３,４,５,６-四氫吡啶
US20090069559A1 (en) Compositions and methods for modulating sirtuin activity
WO2018133795A1 (zh) 一种ezh2抑制剂及其用途
RS59541B1 (sr) Metodi lečenja kancera
WO2017013061A1 (en) Biomarkers associated with lsd1 inhibitors and uses thereof
JP7850460B2 (ja) ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用
BRPI0707689A2 (pt) inibidores de polimerase viral
EP3307909A1 (en) Biomarkers associated with lsd1 inhibitors and uses thereof
Turcotte et al. Synthesis, biological evaluation, and structure–activity relationships of novel substituted N-phenyl ureidobenzenesulfonate derivatives blocking cell cycle progression in S-phase and inducing DNA double-strand breaks
US11767298B2 (en) Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
AU2020379812A1 (en) Selective dual histone deacetylase 6/8 (HDAC6/8) degraders and methods of use thereof
ES2243131B1 (es) Tiamidas derivadas de bifenilo como inhibidores de calpaina.
WO2022140554A1 (en) Small molecule degraders of phosphatidylinositol-5-phosphate 4-kinase type 2 and uses thereof
Ahsan Inhibitor Mediated Bcr-Abl Degradation: A Novel Therapeutic Approach for Chronic Myeloid Leukemia